Several other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Leap Therapeutics from a buy rating to a hold rating in a report on Saturday, March 21st. HC Wainwright decreased their price target on shares of Leap Therapeutics from $3.25 to $2.50 and set a buy rating for the company in a report on Tuesday, March 17th. Robert W. Baird assumed coverage on shares of Leap Therapeutics in a report on Monday, February 10th. They set an outperform rating and a $6.00 price target for the company. Finally, Raymond James set a $2.50 price target on shares of Leap Therapeutics and gave the stock an outperform rating in a report on Tuesday, March 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $3.06.
Shares of LPTX traded up $0.07 during mid-day trading on Thursday, hitting $1.49. The company’s stock had a trading volume of 172,545 shares, compared to its average volume of 873,655. The firm has a 50-day moving average price of $2.03 and a 200 day moving average price of $1.46. The stock has a market capitalization of $54.77 million, a price-to-earnings ratio of -0.99 and a beta of 1.70. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.50 and a quick ratio of 0.50. Leap Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $3.18.
An institutional investor recently bought a new position in Leap Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Leap Therapeutics Inc (NASDAQ:LPTX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 23,523 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.10% of Leap Therapeutics as of its most recent filing with the Securities & Exchange Commission. 13.70% of the stock is currently owned by institutional investors and hedge funds.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Recommended Story: Mutual Funds
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.